---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-080770"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:41:21.400960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iovance Biotherapeutics closes $172.5M public offering of 23M shares at $7.50/share

## Summary
- Closed underwritten public offering of 23,000,000 shares at $7.50 per share.
- Gross proceeds $172.5M; net proceeds expected ~$161.4M after discounts and expenses.
- Proceeds to fund lifileucel commercial launch prep, iCTC manufacturing, and clinical programs.
- Full exercise of underwriters' option to purchase an additional 3 million shares.
- Goldman Sachs & Co. LLC and Jefferies LLC acted as joint lead book-running managers.

## SEC filing metadata
- accession: 0001104659-23-080770
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923080770/0001104659-23-080770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923080770/tm2320915d5_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-080770
- JSON: https://secwatch.observer/filing/0001104659-23-080770.json
- Plain text: https://secwatch.observer/filing/0001104659-23-080770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.